DAZTRODE Trademark

Trademark Overview

On Wednesday, January 21, 2015, a trademark application was filed for DAZTRODE with the United States Patent and Trademark Office. The USPTO has given the DAZTRODE trademark a serial number of 86510002. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 15, 2024. This trademark is owned by Glaxo Group Limited. The DAZTRODE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines

General Information

Serial Number86510002
Word MarkDAZTRODE
Filing DateWednesday, January 21, 2015
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 15, 2024
Registration Number5279076
Registration DateTuesday, September 5, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 19, 2015

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 15, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events

Event DateEvent Description
Friday, March 15, 2024CANCELLED SEC. 8 (6-YR)
Friday, October 28, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 28, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 28, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 28, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 28, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, September 5, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, December 9, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, December 9, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 5, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, August 2, 20171(B) BASIS DELETED; PROCEED TO REGISTRATION
Tuesday, July 11, 2017NOTICE OF ALLOWANCE CANCELLED
Tuesday, July 25, 2017APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, July 25, 2017TEAS POST PUBLICATION AMENDMENT RECEIVED
Friday, July 14, 2017CORRESPONDENCE E-MAILED
Tuesday, July 11, 2017AMENDMENT AFTER NOA NOT ENTERED
Tuesday, July 11, 2017TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, December 20, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, December 18, 2016SOU EXTENSION 3 GRANTED
Tuesday, December 6, 2016SOU EXTENSION 3 FILED
Tuesday, December 6, 2016SOU TEAS EXTENSION RECEIVED
Saturday, August 6, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 5, 2016SOU EXTENSION 2 GRANTED
Wednesday, June 29, 2016SOU EXTENSION 2 FILED
Friday, July 29, 2016CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, June 29, 2016SOU TEAS EXTENSION RECEIVED
Wednesday, December 23, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 21, 2015SOU EXTENSION 1 GRANTED
Monday, December 21, 2015SOU EXTENSION 1 FILED
Monday, December 21, 2015SOU TEAS EXTENSION RECEIVED
Tuesday, July 14, 2015NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 19, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 19, 2015PUBLISHED FOR OPPOSITION
Wednesday, April 29, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, April 10, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, April 10, 2015ASSIGNED TO LIE
Thursday, March 19, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 18, 2015ASSIGNED TO EXAMINER
Monday, February 2, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, January 24, 2015NEW APPLICATION ENTERED

Related Keywords

daztrode pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological